蒙药绿松石的质量标准研究＊

目的 建立蒙药绿松石的质量标准。方法 收集不同产地绿松石，共10批。观察绿松石样品和粉末的性状并进行理化鉴别；按2020年版《中国药典》（四部）通则方法测定绿松石样品中水分、浸出物含量；采用原子吸收光谱法测定绿松石样品铜元素含量。结果 绿松石为不规则、周围带有黑石的块状物，表面蓝绿色，体重，质硬脆，难砸碎，断面呈贝壳状，蜡样光泽，粉末呈灰绿色，无臭，味淡；理化鉴别结果显示，呈铜盐反应；10批次样品中水分含量为0.41%-3.94%（SD=1.37%），浸出物含量为0.21%-0.81%（SD=0.21%），铜元素含量为3.03%-4.63%（SD=0.63%）。结论 初步拟定绿松石中水分含量不得超多5.0%、浸出物含量不得低于0.10%，铜元素含量应为2.60%-4.84%，制定的标准可用于蒙药材绿松石的质量控制。     

益气逐瘀方治疗早期脊髓型颈椎病临床研究

目的:观察益气逐瘀方治疗早期脊髓型颈椎病的临床疗效。方法:选取40例早期脊髓型颈椎病患者为研究对象,按照区组随机化方法分为对照组和治疗组,每组20例。对照组给予美洛昔康片、盐酸乙哌立松片治疗,治疗组给予益气逐瘀方治疗。对比观察2组患者治疗前后日本骨科协会(JOA)颈椎病评分和视觉模拟评分法(VAS)评分,采用富田庄司提出的方法检测颈椎突出物吸收率和突出率。结果:2组JOA颈椎病评分在治疗2周、3个月、6个月后与治疗前比较,差异均有统计学意义(P<0.05)。治疗组治疗3个月、6个月JOA颈椎病评分均高于同期对照组,差异均有统计学意义(P<0.05)。2组VAS评分在治疗2周、3个月、6个月后与治疗前比较,差异均有统计学意义(P<0.05)。治疗组治疗3个月、6个月VAS评分均低于同期对照组,差异均有统计学意义(P<0.05)。治疗后,治疗组颈椎间盘突出率较治疗前减小,对照组颈椎间盘突出率较治疗前增大,差异均有统计学意义(P<0.05)。治疗组颈椎间盘突出物吸收率高于对照组,差异有统计学意义(P<0.05)。结论:益气逐瘀方能有效缓解早期脊髓型颈椎病患者的颈痛症状,延缓病情进展,具有更好的远期疗效。     

Effects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer

Background

First-line adjuvant chemotherapy options for early-stage colorectal cancer (CRC) include CapeOx (capecitabine, intravenous oxaliplatin) and FOLFOX (intravenous 5-fluorouracil, leucovorin, oxaliplatin). Capecitabine is an oral prodrug analog of 5-fluorouracil, and recent studies have suggested that proton pump inhibitors (PPIs) may detrimentally affect capecitabine efficacy. Conversely, some literature suggests that PPIs may negatively affect CRC itself. To gain insight into the nature of PPIs’ effect on capecitabine and CRC, we investigated their effects on effectiveness of CapeOx versus FOLFOX chemotherapy.

Congenital intestinal diarrhoeal diseases: A diagnostic and therapeutic challenge

Congenital diarrhoeal disorders are a heterogeneous group of inherited malabsorptive or secretory diseases typically appearing in the first weeks of life, which may be triggered by the introduction of distinct nutrients. However, they may also be unrecognised for a while and triggered by exogenous factors later on. In principle, they can be clinically classified as osmotic, secretory or inflammatory diarrhoea. In recent years the disease-causing molecular defects of these congenital disorders have been identified. According to the underlying pathophysiology they can be classified into four main groups:1) Defects of digestion, absorption and transport of nutrients or electrolytes2) Defects of absorptive enterocyte differentiation or polarisation3) Defects of the enteroendocrine cells4) Defects of the immune system affecting the intestineHere, we describe the clinical presentation of congenital intestinal diarrhoeal diseases, the diagnostic work-up and specific treatment aspects.     

去除血型抗体制备O型红细胞的研究

目的建立去除血浆中血型抗体的O型红细胞的制备工艺,为临床提供安全的O型红细胞制剂。方法使用处理后的冰冻干燥A型、B型红细胞膜,分别加入O型红细胞血浆中吸附血浆血型抗体物质,并检测吸附后红细胞的结构和功能。结果使用海藻糖冻干保存红细胞膜可保存其抗原性,吸附后,可去除血浆中抗A、抗B抗体80%—99%,同时红细胞变形指数、ATP、渗透脆性、上清游离Hb含量与吸附前(正常红细胞)比较差异无统计学意义(P>0.05),均在正常参考范围;流式结果显示,吸附后采用离心方法,红细胞膜去除率可达到77%。结论用冰冻干燥红细胞膜去除ABO血型抗体为O型红细胞的他型输注奠定了基础。     

Fructooligosaccharide enhanced absorption and anti-dyslipidemia capacity of tea flavonoids in high sucrose-fed mice

The ingestion of tea flavonoids (TF) and fructooligosaccharide (FOS) contributes to anti-hyperlipidaemia. In the current study, TF or FOS or TF together with FOS were orally administrated to mice fed a high sucrose (HS) diet. UPLC-MS analyses showed that FOS significantly increased the concentrations of urine catechin, epigallocatechin, epicatechin gallate, epigallocatechin gallate and gallocatechin gallate. The mice fed with HS for continuous 8?weeks exhibited severe dyslipidemia and abnormal liver fat accumulation. However, oral administration of FOS or TF or in combination significantly decreased the effects of HS on the serum total cholesterol, total triglycerides, low-density lipoprotein and high-density lipoprotein. Co-treatment of FOS and TF more effectively regulated lipid metabolism by inhibiting lipogenesis. Intake of TF together with FOS reduced the level of dyslipidemia marker (elaidic acid) by increasing anti-oxidative activity than treatments of FOS or TP alone in HS-fed mice. Histological observations of liver confirmed these health benefits.     

在体单向肠灌流法研究细叶远志皂苷的大鼠肠吸收特性

目的：研究细叶远志皂苷在大鼠四个肠段的吸收状况。方法运用大鼠在体单向肠灌流模型,采用重量法,研究细叶远志皂苷在不同肠段的吸收情况。结果在体小肠吸收实验中,细叶远志皂苷可被大鼠全肠段吸收,在十二指肠、空肠、回肠及结肠各肠段的药物吸收速率常数（Ka）分别是0．05922,0．06387,0．06345,0．06409s－1;药物表观吸收系数（Papp）分别是0．03322,0．03751,0．03733,0．04830cm? s－1,结肠段吸收最好（P＜0．001）。结论细叶远志皂苷为全肠道吸收的药物,且结肠部位吸收最好。